Table 2.
Characteristics of PDCs.
| Cell line ID | Prior TKI therapyb | Driver mutation |
|---|---|---|
| YU-1073 | Gefitinib | EGFR L858R/T790Ma |
| YU-1074 | Gefitinib | EGFR D770_N771insG |
| YU-1090 | Gefitinib | EGFR L858R/T790Ma |
| YU-1092 | Gefitinib | EGFR L861Q |
| YU-1093 | Erlotinib | EGFR exon 19 deletiona |
| YU-1094 | Gefitinib | EGFR L858Ra |
| YU-1099 | Gefitinib | EGFR G719C/S768Ia |
| YU-1152 | Erlotinib | EGFR L858Ra |
| YU-1091 | Afatinib + Ruxolitinib | EGFR L858Ra |
| YU-1088 | Osimertinib | EGFR exon 19 deletiona |
| YU-1089 | Olmutinib | EGFR exon 19 deletiona |
| YU-1095 | Osimertinib | EGFR exon 19 deletiona |
| YU-1096 | Osimertinib | EGFR L858R |
| YU-1097 | Osimertinib | EGFR exon 19 deletion/T790M/C797S |
| YU-1080 | N/A | CD74-ROS1 |
| YU-1081 | Crizotinib | TPM3-ROS1 |
| YU-1082 | N/A | SLC34A2-ROS1 |
| YU-1083 | N/A | SLC34A2-ROS1 |
| YU-1085 | Crizotinib | SLC34A2-ROS1 |
| YU-1075 | Crizotinib | EML4-ALK |
| YU-1076 | Ceritinib | EML4-ALK |
| YU-1077 | Alectinib | EML4-ALK G1202R |
| YU-1070 | N/A | BRAF K601E |
aRoutine genetic testing results were available in re-biopsy samples after disease progression in these cases and confirmed driver mutations detected in corresponding PDCs.
bPDC was generated from advanced lung adenocarcinoma progressing to the annotated therapy.
N/A, not available.